Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
AZD1222
Antibodies
BNT162b2
COVID-19
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
SARS-CoV-2
Vaccine
Waldenstrom Macroglobulinemia
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
20
05
2021
accepted:
12
07
2021
pubmed:
21
7
2021
medline:
19
5
2022
entrez:
20
7
2021
Statut:
ppublish
Résumé
Vaccination against SARS-CoV-2 is considered as the most important preventive strategy against COVID-19, but its efficacy in patients with hematological malignancies is largely unknown. We investigated the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with Waldenstrom Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). After the first dose of the vaccine, on D22, WM/CLL/NHL patients had lower NAb titers compared to controls: the median NAb inhibition titer was 17% (range 0-91%, IQR 8-27%) for WM/CLL/NHL patients versus 32% (range 2-98%, IQR 19-48%) for controls (P < 0.001). Only 8 (14%) patients versus 114 (54%) controls developed NAb titers ≥ 30% on D22 (p < 0.001). Our data indicate that the first dose of both BNT162b2 and AZD1222 leads to lower production of NAbs against SARS-CoV-2 in patients with WM/CLL/NHL compared to controls of similar age and gender and without malignant disease. Even though the response rates were not optimal, vaccination is still considered essential and if possible should be performed before treatment initiation. These patients with suboptimal responses should be considered to be prioritized for booster doses.
Identifiants
pubmed: 34283338
doi: 10.1007/s10238-021-00746-4
pii: 10.1007/s10238-021-00746-4
pmc: PMC8290394
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-323Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Blood. 2021 Jul 1;137(26):3674-3676
pubmed: 33861315
Am J Hematol. 2021 Jul 1;96(7):E257-E259
pubmed: 33837984
J Hematol Oncol. 2021 May 17;14(1):81
pubmed: 34001183
Expert Rev Hematol. 2018 Jan;11(1):57-70
pubmed: 29160119
Am J Hematol. 2021 Sep 1;96(9):E321-E324
pubmed: 34028867
Leukemia. 2020 Sep;34(9):2354-2363
pubmed: 32647324
Blood. 2011 Dec 22;118(26):6769-71
pubmed: 22058114
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Leukemia. 2020 Nov;34(11):3047-3049
pubmed: 32855439
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Leukemia. 2021 Dec;35(12):3573-3577
pubmed: 34023850
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
JAMA. 2021 Apr 27;325(16):1670-1671
pubmed: 33625464
Lancet Oncol. 2021 May;22(5):581-583
pubmed: 33812495
Hemasphere. 2021 Feb 17;5(3):e547
pubmed: 33623886
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Leukemia. 2021 Sep;35(9):2703-2705
pubmed: 33986431
Ann Oncol. 2021 Aug;32(8):1051-1053
pubmed: 33932501
Cancer Immunol Immunother. 2006 Feb;55(2):197-209
pubmed: 16025268
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279